Actelion Ltd - Product Pipeline Review - Q2 2011

Global Markets Direct, July 2011, Pages: 65

Actelion Ltd – Product Pipeline Review – Q2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Actelion Ltd - Product Pipeline Review - Q2 2011” provides data on the Actelion Ltd’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Actelion Ltd’s corporate website, SEC filings, investor presentations and featured press releases, both from Actelion Ltd and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Actelion Ltd - Brief Actelion Ltd overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Actelion Ltd human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Actelion Ltd with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Actelion Ltd’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Actelion Ltd’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Actelion Ltd in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Actelion Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Actelion Ltd.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Actelion Ltd and identify potential opportunities in those areas.

List of Tables
List of Figures
Actelion Ltd Snapshot
Actelion Ltd Overview
Key Information
Key Facts
Actelion Ltd – Research and Development Overview
Key Therapeutic Areas
Actelion Ltd – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Actelion Ltd – Pipeline Products Glance
Actelion Ltd – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Actelion Ltd Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Actelion Ltd–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Actelion Ltd – Drug Profiles
Macitentan
Product Description
Mechanism of Action
R&D Progress
Pivlaz
Product Description
Mechanism of Action
R&D Progress
Selexipag
Product Description
Mechanism of Action
R&D Progress
Tezosentan
Product Description
Mechanism of Action
R&D Progress
ACT-129968
Product Description
Mechanism of Action
R&D Progress
ACT-179811
Product Description
Mechanism of Action
R&D Progress
ACT128800
Product Description
Mechanism of Action
R&D Progress
Antibiotic
Product Description
Mechanism of Action
R&D Progress
CRTH2 Antagonist
Product Description
Mechanism of Action
R&D Progress
Macitentan
Product Description
Mechanism of Action
R&D Progress
Zavesca
Product Description
Mechanism of Action
R&D Progress
S1P1 Agonist
Product Description
Mechanism of Action
R&D Progress
Drug for Multiple sclerosis
Product Description
Mechanism of Action
R&D Progress
Actelion Ltd – Pipeline Analysis
Actelion Ltd – Pipeline Products by Therapeutic Class
Actelion Ltd - Pipeline Products By Target
Actelion Ltd – Pipeline Products by Route of Administration
Actelion Ltd – Pipeline Products by Molecule Type
Actelion Ltd – Recent Pipeline Updates
Actelion Ltd - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Almorexant
Palosuran
Tezosentan
Ventavis + Sildenafil + Bosentan
Actelion Ltd – Company Statement
Actelion Ltd – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Actelion Ltd, Deals Volume Summary, 2004 to YTD 2011
Actelion Ltd, Deals Summary By Region, 2004 to YTD 2011
Actelion Ltd, Deals Summary, 2004 to YTD 2011
Actelion Ltd Detailed Deal Summary
Asset Purchase
Actelion Pharmaceuticals acquires office building in South San Francisco
Acquisition
Actelion Acquires CoTherix
Cerep Acquires Hesperion
Debt Offering
Actelion Pharmaceuticals Completes Public Offering Of Convertible Bonds For $368 Million
Nippon Shinyaku Enters Into Agreement With Actelion Pharmaceuticals
Roche Enters Into Co-Development Agreement With Actelion
Roche Terminates Co-Development Agreement With Actelion
Licensing Agreements
GlaxoSmithKline Enters Into An Agreement With Actelion
Actelion Enters Into Licensing Agreement With Nippon Shinyaku For Japan
Actelion Enters Into Licensing Agreement With UCB
Actelion Extends Licensing Agreement With Celltech For Zavesca
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Actelion Ltd – Pipeline by Therapy Area and Indication, 2011
Actelion Ltd – Pipeline by Stage of Development, 2011
Actelion Ltd – Monotherapy Products in Pipeline, 2011
Actelion Ltd – Phase III, 2011
Actelion Ltd - Phase II, 2011
Actelion Ltd - Phase I, 2011
Actelion Ltd - Pipeline By Therapeutic Class, 2011
Actelion Ltd - Pipeline By Target, 2011
Actelion Ltd – Pipeline By Route of Administration, 2011
Actelion Ltd – Pipeline By Molecule Type, 2011
Actelion Ltd – Recent Pipeline Updates, 2011
Actelion Ltd - Discontinued Pipeline Products, 2010
Actelion Ltd, Subsidiaries
Actelion Ltd, Deals Summary, 2004 to YTD 2011
Actelion Ltd, Deals Summary by Region, 2004 to YTD 2011
Actelion Ltd, Deals Summary, 2004 to YTD 2011

List of Figures
Actelion Ltd – Pipeline by Therapy Area and Indication, 2011
Actelion Ltd – Pipeline by Stage of Development, 2011
Actelion Ltd – Monotherapy Products in Pipeline, 2011
Actelion Ltd – Pipeline By Therapeutic Class, 2011
Actelion Ltd - Pipeline By Target, 2011
Actelion Ltd – Pipeline By Route of Administration, 2011
Actelion Ltd – Pipeline By Molecule Type, 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• SunGard - Profile - US
• Insight into Samsung Electronics' Notebook PC Business Model
• Scientific Games Corporation - Company Analysis
• Accenture - Profile - US
• Dell - Profile - US
• HP - Profile - US
• IBM - Profile - US